Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02389959 · ClinicalTrials.gov registry record · Phase 4
Intranasal Bevacizumab for HHT-Related Epistaxis
A Phase 4 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT02389959: Completed Phase 4 study, sponsored by Stanford University.
NCT02389959 is a Phase 4 study that has completed, run by Stanford University. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02389959, a Phase 4 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
This is a randomized, controlled, double-blind, placebo-controlled trial of intranasal Avastin (bevacizumab) injection versus saline control for control of HHT-related epistaxis when used in conjunction with bipolar electrocautery.
Interventions
- DRUG Bevacizumab
- DRUG Placebo (Saline)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2014-08-04 |
| Est. Completion | 2020-01-23 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02389959
The ClinicalTrials.gov registry entry for NCT02389959 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT02389959 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02389959 about?
NCT02389959 is a clinical study titled "Intranasal Bevacizumab for HHT-Related Epistaxis". This is a randomized, controlled, double-blind, placebo-controlled trial of intranasal Avastin (bevacizumab) injection versus saline control for control of HHT-related epistaxis when used in conjunction with bipolar electrocautery.
What is the current status of trial NCT02389959?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2014-08-04. Estimated completion is 2020-01-23.
What interventions are being tested in trial NCT02389959?
The interventions under investigation include: Bevacizumab (DRUG), Placebo (Saline) (DRUG).
Who is sponsoring clinical trial NCT02389959?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.